InvestorsHub Logo
Followers 18
Posts 1568
Boards Moderated 0
Alias Born 11/01/2018

Re: xodcode post# 227736

Wednesday, 01/01/2020 12:53:08 PM

Wednesday, January 01, 2020 12:53:08 PM

Post# of 469844
Right! AVXL CTAD 2-73 information showed blockbuster results. There is no other drug that comes close to these positive results. Should be the new SOC with these results and proven safety. The market was silent with it as daily volumes increased since then. GL

Propensity score matching (PSM) was applied using Linear Mixed Effects (LME) models including descriptors of age, sex, SIGMAR1 p.Q2P carrier status, APOE4 allele and MMSE at baseline to select patients with similar baseline characteristics and any confounding factors between AD patients in the Phase 2a ANAVEX®2-73 (blarcamesine) cohort and AD patients from the ADNI control cohort.

Change in MMSE score from baseline at week 104 of matched cohorts was assessed. It showed that ANAVEX®2-73 (blarcamesine) high dose cohort had a significantly lower MMSE decline (-1.1) compared to the ADNI control cohort (-4.4) at week 104 (p < 0.01).


https://finance.yahoo.com/news/anavex-life-sciences-presents-anavex-120010950.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News